FAQs

The Amylin-Based Therapeutics Summit is the industry's first conference dedicated exclusively to advancing amylin therapeutics. Taking place in Boston from December 1-3, 2026, the meeting brings together experts from pharma, biotech, academia, and investment communities to discuss amylin receptor biology, clinical development, receptor signalling, translational science, and next-generation obesity drug development strategies.

The Amylin-Based Therapeutics Summit takes place December 1-3, 2026, in Boston, Massachusetts. The event includes two pre-conference workshops followed by two days of scientific presentations, discussions, and network

The summit is designed for professionals working in:

• Obesity and metabolic disease drug development
• Diabetes research
• Translational medicine
• Clinical development
• Pharmacology and receptor biology
• Discovery and preclinical R&D
• Business development and strategy
• Biotech leadership and investment

Attendees include scientific leaders and decision-makers from companies such as Eli Lilly, Novo Nordisk, Zealand Pharma, iBio, Antag Therapeutics, Pep2Tango, and other organizations developing amylin-based therapies.

The agenda focuses on key challenges and opportunities shaping the future of amylin drug development, including:

• Amylin receptor signaling and pharmacology
• Receptor subtype selectivity (AMY1, AMY2, and AMY3)
• DACRA versus selective amylin agonist strategies
• Clinical lessons from leading amylin programs
• Translational models and species differences
• Efficacy versus tolerability optimization
• Body composition and quality of weight loss
• Novel delivery platforms including peptides, antibodies, and oral therapeutics
• Clinical trial design and patient selection strategies

These topics are addressed through presentations, workshops, debates, roundtables, and networking sessions.

Unlike larger obesity, diabetes, or metabolic disease meetings, the Amylin-Based Therapeutics Summit is entirely focused on amylin science and drug development. Rather than competing with hundreds of parallel sessions, attendees join a highly targeted community focused on solving amylin-specific scientific, translational, and clinical challenges. The event will involve approximately 50+ senior-level participants, allowing for deeper networking and more focused technical discussions.

The summit includes multiple networking formats designed to connect attendees with active amylin drug developers, including:

• Speed networking
• Interactive workshops
• Roundtable discussions
• Scientific poster sessions
• Structured debates
• Networking breaks and receptions

These formats are designed to facilitate meaningful conversations and collaboration across the amylin ecosystem.

Yes. Researchers can submit scientific posters for review and presentation. Poster sessions provide an opportunity to showcase new discoveries, gain feedback from leading experts, and build visibility within the rapidly growing amylin research community.

More information about poster submissions can be found here.

The summit brings together representation from leading pharmaceutical companies, emerging biotech innovators, academic institutions, and investors involved in obesity and metabolic disease drug development. Speakers include experts from Eli Lilly, Novo Nordisk, Zealand Pharma, iBio, Antag Therapeutics, I2O Therapeutics, Pep2Tango, Perpetual Medicines, Fractyl Laboratories, University of Zurich, University of Oklahoma, and University of Otago.

Beyond obesity, researchers are investigating potential applications for amylin-based therapeutics in:

• Type 1 diabetes
• MASH (Metabolic Dysfunction-Associated Steatohepatitis)
• Kidney disease
• Cardiovascular disease
• Weight maintenance
• Addiction and alcohol use disorders
• Sleep disorders
• Neurodegenerative diseases such as Alzheimer's disease

The summit explores both established and emerging opportunities where amylin biology may create future therapeutic value.